Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v3.19.2
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
CONSOLIDATED STATEMENTS OF OPERATIONS    
Revenues
Operating expenses:    
General and administrative 298,951 313,094
Total operating expenses 298,951 313,094
Loss from operations (298,951) (313,094)
Other income (expense):    
Loss on fair value adjustment - derivatives (12,023)
Interest expense (263,092) (317,194)
Amortization of interest- beneficial conversion feature (80)
Total other income (expense) (263,172) (329,217)
Loss before provision for income taxes (562,123) (642,311)
Net loss (562,123) (642,311)
Net loss attributable to noncontrolling interest 3,158 3,226
Net loss attributable to TransBioTec, Inc. $ (558,965) $ (639,085)
Net loss per share    
(Basic and fully diluted) $ (0.005) $ (0.007)
Weighted average number of common shares outstanding 114,542,302 97,823,538